These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
959 related articles for article (PubMed ID: 33756459)
1. Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. Venketasubramanian N; Anderson C; Ay H; Aybek S; Brinjikji W; de Freitas GR; Del Brutto OH; Fassbender K; Fujimura M; Goldstein LB; Haberl RL; Hankey GJ; Heiss WD; Lestro Henriques I; Kase CS; Kim JS; Koga M; Kokubo Y; Kuroda S; Lee K; Lee TH; Liebeskind DS; Lip GYH; Meairs S; Medvedev R; Mehndiratta MM; Mohr JP; Nagayama M; Pantoni L; Papanagiotou P; Parrilla G; Pastori D; Pendlebury ST; Pettigrew LC; Renjen PN; Rundek T; Schminke U; Shinohara Y; Tang WK; Toyoda K; Wartenberg KE; Wasay M; Hennerici MG Cerebrovasc Dis; 2021; 50(3):245-261. PubMed ID: 33756459 [TBL] [Abstract][Full Text] [Related]
2. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
3. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784 [TBL] [Abstract][Full Text] [Related]
6. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. Choudhury A; Mukherjee S J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 and renin-angiotensin system modulators: what do we know so far? de la Cruz A; Ashraf S; Vittorio TJ; Bella JN Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817 [TBL] [Abstract][Full Text] [Related]
9. [Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks?]. El-Hage W; Hingray C; Lemogne C; Yrondi A; Brunault P; Bienvenu T; Etain B; Paquet C; Gohier B; Bennabi D; Birmes P; Sauvaget A; Fakra E; Prieto N; Bulteau S; Vidailhet P; Camus V; Leboyer M; Krebs MO; Aouizerate B Encephale; 2020 Jun; 46(3S):S73-S80. PubMed ID: 32370984 [TBL] [Abstract][Full Text] [Related]
10. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise. Joseph S; Nair B; Nath LR Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox. Javanmard SH; Heshmat-Ghahdarijani K; Vaseghi G Infect Control Hosp Epidemiol; 2021 Jan; 42(1):118-119. PubMed ID: 32362297 [No Abstract] [Full Text] [Related]
12. Neurological Sequelae of COVID-19. Ahmad SJ; Feigen CM; Vazquez JP; Kobets AJ; Altschul DJ J Integr Neurosci; 2022 Apr; 21(3):77. PubMed ID: 35633158 [TBL] [Abstract][Full Text] [Related]
13. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. Shukla AK; Banerjee M High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533 [TBL] [Abstract][Full Text] [Related]
15. Human and novel coronavirus infections in children: a review. Rajapakse N; Dixit D Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199 [TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
17. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]